Henrik T. Rasmussen

The primary goal of early phase development is to gain a fundamental knowledge of the chemistry of drug substances and drug products to facilitate optimization of synthetic schemes and drug product formulations. At the same time, methods are required for release and stability studies to support clinical trials. Ultimately, the knowledge gained during early development translates into designing control methods for commercial supplies. Our approach to meeting this challenge is based upon the use of a primary method along with orthogonal methods. This paper will discuss the overall strategy, with an emphasis on the chromatographic conditions selected to provide systematic othogonality for a broad range of drugs. Case studies will be presented to demonstrate the utility of orthogonal methods to resolve issues that could not have been addressed using a single release and stability method.